Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

H5166

Sigma-Aldrich

Erythropoietin human

EPO, recombinant, expressed in HEK 293 cells, suitable for cell culture

Synonym(s):

EPO

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
11096-26-7
MDL number:
MFCD00131025
UNSPSC Code:
12352202
NACRES:
NA.77

biological source

human

Quality Level

100

recombinant

expressed in HEK 293 cells

Assay

≥95% (SDS-PAGE)

form

lyophilized powder

potency

≤5.0 ng/mL ED50

quality

endotoxin tested

mol wt

dimer 36 kDa (glycosylated)

packaging

pkg of 10 μg

storage condition

avoid repeated freeze/thaw cycles

technique(s)

cell culture | mammalian: suitable

impurities

≤1 EU/μg

UniProt accession no.

P01588

storage temp.

−20°C

Gene Information

human ... EPO(2056)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

EPO has been cloned from various species including human, murine, canine, and others. The mature proteins from the various species are highly conserved and exhibit greater than 80% amino acid sequence identity. EPO contains three N-linked glycosylation sites. The glycosylation of erythropoietin is required for the biological activities of erythropoietin in vivo.

Biochem/physiol Actions

Erythropoietin (EPO), produced primarily by the kidney, is the primary regulatory factor of erythropoiesis. It promotes the proliferation, differentiation, and survival of the erythroid progenitors. Erythropoietin stimulates erythropoiesis by inducing growth and differentiation of burst forming units and colony forming units into mature red blood cells. EPO produced by kidney cells is increased in response to hypoxia or anemia. The biological effects of erythropoietin are mediated by the erythropoietin receptor, which binds EPO with high affinity and is a potent EPO antagonist.
Erythropoietin is a glycoprotein that is the principal regulator of red blood cell growth and differentiation.

Preparation Note

Human EPO is expressed as a glycosylated 36 kDa monomer in human HEK 293 cells. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.

Analysis Note

The specific activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line).

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

H5166-VAR:
H5166-10UG:
H5166-5UG:
H5166-BULK:
H5166-10UG-PW:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCJ9962
029M4845V
MKCH5150
MKCH0321
MKCG5984

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

IL-3 human Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Sigma-Aldrich

SRP3090

IL-3 human

Valganciclovir Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1626

Valganciclovir Hydrochloride

Rajasekhar N V S Suragani et al.
Nature medicine, 20(4), 408-414 (2014-03-25)
Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, which is EPO independent. Here we investigated regulation of
Cynthia So-Osman et al.
Anesthesiology, 120(4), 839-851 (2014-01-16)
Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. In a factorial design, adult elective hip- and
François Roubille et al.
Cardiovascular drugs and therapy, 27(4), 315-331 (2013-05-23)
Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues. It has been shown to inhibit apoptosis by activating pro-survival pathways in the myocardium, to mobilize endothelial progenitor
Russia Ha-Vinh Leuchter et al.
JAMA, 312(8), 817-824 (2014-08-27)
Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies. To determine if there is an association between early high-dose recombinant
H Franklin Bunn
Cold Spring Harbor perspectives in medicine, 3(3), a011619-a011619 (2013-03-05)
During the past century, few proteins have matched erythropoietin (Epo) in capturing the imagination of physiologists, molecular biologists, and, more recently, physicians and patients. Its appeal rests on its commanding role as the premier erythroid cytokine, the elegant mechanism underlying
View All Related Papers

Articles

Hematopoietic Cytokines

Read article on hematopoietic cytokines and hematopoiesis

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service